Treatment of Alcohol Use Disorder in Patients with Alcoholic Liver Disease.
Treatment of Alcohol Use Disorder in Patients with Alcoholic Liver Disease.
复制标题
治疗酒精性肝病患者酒精疾病。
DOI：
10.1016/j.amjmed.2016.10.004
复制
发表时间：
2017-02
期刊：
影响因子：
--
通讯作者：
Lee MR
中科院分区：
文献类型：
--
作者：
Leggio L;Lee MR
酒精是全球肝病的主要原因。虽然戒酒是酒精性肝病患者的关键治疗目标，但这些患者很少获得酒精使用障碍的心理，行为和/或药物治疗。心理社会和行为疗法包括12步促进法、简短干预、认知行为疗法和动机增强疗法。除了美国食品和药物管理局（FDA）批准用于酒精使用障碍的药物（双硫仑，纳洛酮和阿坎酸）外，最近确定潜在新治疗方法的努力已经产生了有希望的候选药物疗法。最后，在酒精使用障碍和酒精性肝病患者的管理中，需要更多的努力来整合跨学科的治疗方法，以患者为中心。
Alcohol is a leading cause of liver disease worldwide. Although alcohol abstinence is the crucial therapeutic goal for patients with alcoholic liver disease, these patients have less access to psychosocial, behavioral and/or pharmacological treatments for alcohol use disorder. Psychosocial and behavioral therapies include 12-step facilitation, brief interventions, cognitive behavioral therapy, and motivational enhancement therapy. In addition to medications approved by the Food and Drug Administration (FDA) for alcohol use disorder (disulfiram, naltrexone and acamprosate), recent efforts to identify potential new treatments have yielded promising candidate pharmacotherapies. Finally, more efforts are needed to integrate treatments across disciplines toward patient-centered approaches in the management of patients with alcohol use disorder and alcoholic liver disease.